Mallinckrodt plc, a specialty pharmaceutical company, has entered into an agreement under which it will sell certain hemostasis products to Baxter International Inc. for approximately $185 million, with upfront payment of $153 million, inclusive of existing inventory, and the remainder in potential future milestones. Baxter will assume other expenses, including contingent liabilities associated with Preveleak. Baxter is a…